Bellerophon Therapeutics, Inc (BLPH)

Etorro trading 970x250
Bellerophon Therapeutics, Inc (BLPH) Logo

About Bellerophon Therapeutics, Inc

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its products include INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 2 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; that has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that is in Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension, pulmonary hypertension associated with pulmonary edema from high altitude sickness, and COVID-19 patients. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey. Address: 184 Liberty Corner Road, Warren, NJ, United States, 07059

Bellerophon Therapeutics, Inc News and around…

Latest news about Bellerophon Therapeutics, Inc (BLPH) common stock and company :

12 Health Care Stocks Moving In Thursday's Pre-Market Session
30 Sep, 2021 FinancialContent

Gainers OptimizeRx (NASDAQ:OPRX) stock increased by 12.12% to $84.05 during Thursday's pre-market session. The ...

Implied IWC Analyst Target Price: $204
29 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Micro-Cap ETF (IWC), we found that the implied analyst target price for the ETF based upon its underlying holdings is $204.00 per unit.

Bellerophon to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
07 Sep, 2021 FinancialContent
Here's Why We're Watching Bellerophon Therapeutics' (NASDAQ:BLPH) Cash Burn Situation
03 Sep, 2021 Yahoo! Finance

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

The Math Shows FDM Can Go To $76
24 Aug, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Dow Jones Select MicroCap Index Fund ETF (FDM), we found that the implied analyst target price for the ETF based upon its underlying holdings is $75.53 per unit.

The Daily Biotech Pulse: Cara's Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal
24 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Lows On Monday
23 Aug, 2021 FinancialContent

Before 10 a.m. ET on Monday, 29 stocks hit new 52-week lows. Significant Points: The largest company by ...

The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
17 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Bellerophon Provides Clinical Program Update and Reports Second Quarter 2021 Financial Results
05 Aug, 2021 FinancialContent
Analysts See 27% Upside For FDM
21 Jul, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Dow Jones Select MicroCap Index Fund ETF (FDM), we found that the implied analyst target price for the ETF based upon its underlying holdings is $74.79 per unit.

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
29 Jun, 2021 FinancialContent

Gainers Cerevel Therapeutics Hldg (NASDAQ:CERE) shares moved upwards by 42.0% to $17.85 during Tuesday's pre-market ...

Hedge Funds Are Coming Back To Bellerophon Therapeutics, Inc. (BLPH)
29 Jun, 2021 Yahoo! Finance

A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]

45 Biggest Movers From Yesterday
24 Jun, 2021 FinancialContent

Gainers Entera Bio Ltd. (NASDAQ: ENTX) shares surged 44.8% to close at $6.50 on Wednesday after the company reported topline ...

Mid-Afternoon Market Update: Patterson Companies Drops On Earnings Miss; Entera Bio Shares Gain
23 Jun, 2021 FinancialContent

Toward the end of trading Wednesday, the Dow traded down 0.08% to 33,918.98 while the NASDAQ rose 0.16% to 14,276.41. The S&P also ...

Why Entera Bio, Orphazyme, Bellerophon Are Moving Today
23 Jun, 2021 FinancialContent

Entera Bio Ltd. (NASDAQ: ENTX), Orphazyme A/S (NASDAQ: ORPH) and Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) are among the biggest ...

12 Health Care Stocks Moving In Wednesday's Intraday Session
23 Jun, 2021 FinancialContent

Gainers Orphazyme (NASDAQ:ORPH) shares moved upwards by 32.66% to $7.92 during Wednesday's regular session. As of ...

Mid-Day Market Update: Crude Oil Rises Over 1%; Gemini Therapeutics Shares Slide
23 Jun, 2021 FinancialContent

Midway through trading Wednesday, the Dow traded up 0.01% to 33,948.64 while the NASDAQ rose 0.19% to 14,280.41. The S&P also rose, ...

31 Stocks Moving In Wednesday's Mid-Day Session
23 Jun, 2021 FinancialContent

Gainers Entera Bio Ltd. (NASDAQ: ENTX) shares jumped 58% to $7.09 after the company reported topline Phase 2 bone mineral density ...

8 Hot Biotech Penny Stocks For Your July 2021 Watch List
23 Jun, 2021 FinancialContent
Mid-Morning Market Update: Markets Rise; IHS Markit Earnings Beat Views
23 Jun, 2021 FinancialContent

Following the market opening Wednesday, the Dow traded up 0.14% to 33,991.54 while the NASDAQ rose 0.38% to 14,307.88. The S&P also ...

Biogen (BIIB) Initiates Late-Stage Study on Lupus Candidate
18 Jun, 2021 Yahoo! Finance

Biogen (BIIB) is developing its monoclonal antibody candidate, BIIB059, as a potential treatment for active systemic lupus erythematosus.

VBI Vaccines (VBIV) Up on Glioblastoma Drug Fast Track Status
09 Jun, 2021 Yahoo! Finance

VBI Vaccines (VBIV) is developing VBI-1901 as a potential treatment of recurrent glioblastoma patients.

Arena (ARNA) Starts Phase II Study on Coronary Drug Temanogrel
09 Jun, 2021 Yahoo! Finance

Arena (ARNA) is developing temanogrel in a phase II study as potential treatment for coronary microvascular obstruction in patients undergoing percutaneous coronary intervention.

Bellerophon to Present at the Jefferies Virtual Healthcare Conference
27 May, 2021 FinancialContent
Bellerophon Appoints Naseem Amin, M.D. as Chairman of its Board of Directors
26 May, 2021 FinancialContent

Dr. Amin Has Served as an Independent Director Since 2015 and Succeeds Jonathan Peacock Following Mr. Peacock’s Retirement from the Company’s Board

Reata (RETA) Soars on Potential Omaveloxolone NDA Filing
20 May, 2021 Yahoo! Finance

The FDA asks Reata (RETA) to submit a pre-NDA meeting request to discuss omaveloxolone study data and cancel its previous request for a more general Type C meeting, boosting chances of an early NDA filing.

Iovance (IOVA) Falls on Negative Lifileucel Regulatory Update
20 May, 2021 Yahoo! Finance

Iovance (IOVA) announces delay in BLA submission for its lead pipeline candidate, lifileucel for metastatic melanoma due to potency assay issue.

The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts
14 May, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use
13 May, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Bellerophon Provides Clinical Program Update and Reports First Quarter 2021 Financial Results
11 May, 2021 FinancialContent

Bellerophon Therapeutics, Inc (BLPH) is a NASDAQ Common Stock listed in , ,

970x250